Clinical trial
Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression
NCT07929740 is registered in ClinicalTrials.gov with Kura Oncology, Inc. as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started October 2026. Interventional study, Phase 1, 126 participants (estimated). Lead sponsor Kura Oncology, Inc.. Primary measures: To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts...; To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts... and 3 more.
How it compares
457 similar trials: same condition (Myelodysplastic Syndromes) and phase
Registry record
As filed in ClinicalTrials.gov.
- Title
- Relative Bioavailability and Bioequivalence Study of Ziftomenib Drug Products in Participants With Relapsed/Refractory AML With NPM1 Mutation, or With Relapsed/Refractory AML or MDS With Mutations Associated With MEIS1 Overexpression
- Lead sponsor
- Kura Oncology, Inc.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 30, 2026
- Completion date
- February 28, 2029
- Enrollment
- 126 (estimated)
- Sites
- Not reported
Conditions
MeSH condition names; the registry's own terms follow.
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Recurrence
Registry terms: myelodysplastic syndrome (mds)/aml, myeloid leukemia, acute
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Lead sponsor
- Kura Oncology, Inc.
Arms
As registered; 3 arms.
| Arm | Type | Interventions |
|---|---|---|
| Cohort A | Experimental | Ziftomenib |
Show registry wordingSequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2) | ||
| Cohort B | Experimental | Ziftomenib |
Show registry wordingSequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2) | ||
| Cohort C | Experimental | Ziftomenib |
Show registry wordingSequential administration of oral formulations (Part 1) followed by optional treatment continuation (Part 2) | ||
Primary endpoints
Registered primary outcome measures; 5 primary.
| Measure | Time frame |
|---|---|
| To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C) | During the first 56 days of ziftomenib |
Show registry wordingMaximum plasma concentration at steady state (Cmax,ss) | |
| To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) | During the first 56 days of ziftomenib |
Show registry wordingPlasma concentration observed at end of dosing interval at steady state (Cτ) | |
| To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A, B and C) | During the first 56 days of ziftomenib |
Show registry wordingArea under the concentration-time curve from time 0 to dosing interval at steady state (AUC0-τ,ss) | |
| To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) | During the first 56 days of ziftomenib |
Show registry wordingTime to Cmax,ss (Tmax,ss) | |
| To determine the plasma PK parameters of ziftomenib following oral (PO) administration (Part 1: Cohorts A and B) | During the first 56 days of ziftomenib |
Show registry wordingCavg,ss | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Ziftomenib
- US 12410184; expires July 16, 2044; assignee Kura Oncology, Inc.
- US 12521396; expires July 16, 2044; assignee not stated
- US 11944627; expires September 6, 2038; assignee Kura Oncology, Inc.
- US 10781218; expires March 15, 2037; assignee Kura Oncology, Inc., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- US 11673898; expires March 15, 2037; assignee Kura Oncology, Inc., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
- +3 more patents
Lead sponsor's other trials
Kura Oncology, Inc., most recent start first.
+12 more trials See the organization page
Similar trials
Same condition (Myelodysplastic Syndromes) and phase, most recent start first.
+452 more trials See the condition page